Identification of effective combination therapies is critical to address the emergence of drug-resistant cancers, but direct screening of all possible drug combinations is infeasible. Here we introduce a CRISPR-based double knockout (CDKO) system that improves the efficiency of combinatorial genetic screening using an effective strategy for cloning and sequencing paired single guide RNA (sgRNA) libraries and a robust statistical scoring method for calculating genetic interactions (GIs) from CRISPR-deleted gene pairs. We applied CDKO to generate a large-scale human GI map, comprising 490,000 double-sgRNAs directed against 21,321 pairs of drug targets in K562 leukemia cells and identified synthetic lethal drug target pairs for which corresponding drugs exhibit synergistic killing. These included the BCL2L1 and MCL1 combination, which was also effective in imatinib-resistant cells. We further validated this system by identifying known and previously unidentified GIs between modifiers of ricin toxicity. This work provides an effective strategy to screen synergistic drug combinations in high-throughput and a CRISPR-based tool to dissect functional GI networks.
A r t i c l e s Despite progress in the development of targeted cancer therapies, evolution of resistance is common. To counter resistance, combination therapy is rapidly becoming the standard of care in a range of cancers where single agents are ineffective 1 . Repurposing existing drugs in combinations could provide new therapeutic possibilities with reduced cost and time for development, while potentially minimizing side effects by lowering the dosage requirement for each drug [1] [2] [3] . Discovering such drug combinations, however, is a major challenge since the number of possible combinations is too large to be empirically validated using traditional assays 4 .
GI maps have been used successfully to study the coordinated behaviors of genes, and consist of systematic pairwise measures of the extent to which the phenotype of one mutation is modulated by the presence of a second mutation 5 . The pattern of synergistic and buffering interactions serves as a 'phenotypic signature' for each gene, and can be used to cluster genes with similar functions into pathways and complexes. These maps have been useful tools for predicting gene function, allowing dissection of complexes and pathways 6-10 in a range of organisms 5, 7, 9, [11] [12] [13] [14] [15] . Notably, a recent study, using a yeast GI map, identified synthetic lethal interactions that were conserved in mammalian cells as potential cancer therapies 16 . We 15 and others 17 recently demonstrated scalable, rapid strategies to create pooled combinatorial short hairpin RNA (shRNA) and microRNA libraries that facilitated the use of GI maps in mammalian cells. Creation of such maps using the CRISPR-Cas9 system, which allows for precise gene disruption with minimal off-target effects [18] [19] [20] , would be a transformative tool for dissection of genetic interaction networks.
Here, we report a scalable CRISPR-based double knockout (CDKO) system that enables massively parallel pairwise gene knockout. Although a number of groups have used CRISPR-Cas9 for multiplexed genome engineering [20] [21] [22] [23] , our library design minimizes possible recombination 24, 25 and positional bias while enabling simple cloning and direct paired-end sequencing of sgRNAs. Furthermore, we developed a robust statistical scoring method for GIs from CRISPRdeleted gene pairs. Using this system in K562 chronic myeloid leukemia (CML) cells, we demonstrate two diverse applications: first, we conduct an ultra-high-throughput search for rare interactions, generating, to our knowledge, the largest mammalian GI map to date, comprising ~490,000 double-sgRNAs corresponding to 21,321 drug combinations. Based on the genetic data, we identify synergistic drug target combinations and show that the predicted target pairs translate to potent synergistic drug combinations in cell culture. In a second application, we independently validate the method on a dense network of genetic interactions by creating a GI map that uses interaction patterns to correctly classify known and novel regulators of ricin toxicity into functional complexes.
RESULTS

A scalable, efficient CRISPR double-knockout (CDKO) system
We first aimed to design a pairwise sgRNA expression system that incorporated several key features ( Fig. 1a): (1) efficient double knockout, (2) limited lentiviral vector recombination due to long homologous sequences, (3) compatibility with paired-end deep sequencing, and (4) capacity for easy cloning and multiplexing. We tested two approaches to express pairs of sgRNAs from a lentiviral vector: a dual-promoter system and a single promoter Csy4 (RNase from Pseudomonas aeruginosa) sgRNA system 21 . For the first, we designed a vector to limit homologous sequences by employing two distinct promoters (human and mouse U6) driving expression of each sgRNA (Fig. 1b) . In the second approach, we adapted the Csy4-based synergistic drug combinations for cancer identified in a crisPr screen for pairwise genetic interactions A r t i c l e s multiplex gRNA expression system in which two sgRNAs are transcribed as a single RNA and cleaved into two by Csy4 RNase 21 . We compared the efficiency of both systems to delete GFP and mCherry in cells stably expressing the corresponding targets and Cas9 (or Cas9 and Csy4). We found that the two-promoter system showed far higher double-knockout efficiency (86-88%) than the Csy4-based system (37%) without displaying substantial bias when the orientation of GFP and mCherry sgRNAs was flipped ( Fig. 1b) and thus selected this strategy.
Oligonucleotide pools were separately cloned into lentiviral vectors with either human U6 (hU6) or mouse U6 (mU6) promoters to generate two single-sgRNA libraries (Fig. 1c) . Subsequently, hU6 single-sgRNA cassettes were removed by restriction digest and ligated into the mU6 library to create a CDKO library. This system allows direct pairedend sequencing of double-sgRNA cassettes (Supplementary Fig. 1a,b ) without relying on barcodes. This not only simplifies the structure of the oligos and the cloning steps, but should also limit the potential for confounding results from possible vector recombination, which could lead to incomplete sgRNA pairs or mismatched barcodes. Indeed, a vector with two mU6 promoters exhibited substantially reduced activity and increased recombination ( Supplementary Fig. 1c-f) .
To identify synergistic combinations of drug targets in K562 CML cells, we selected genes that fit a number of criteria ( Fig. 1d ). First, we chose genes with corresponding drugs in TTD 26 , DrugBank 27 , or IUPHAR/BPS 28 . To enhance the likelihood that targets would have activity in the selected cancer type, we chose genes expressed in K562 cells whose perturbation caused a moderate negative growth phenotype in both CRISPR-Cas9 (ref. 29 ) and shRNA screens 30 we previously performed in K562 cells. To enrich for synergistic pairs, we removed genes with lethal single-gene-deletion phenotypes as their phenotypes would not be further aggravated by additional gene deletions. For the 207 genes that met these criteria ( Supplementary  Table 1 ), we hypothesized that drugs targeting these genes would be toxic to K562 cells, and searched for interactions between them.
To generate the GI map, we selected the three most effective sgRNAs for each gene based on their phenotypes in our previous K562 genome-wide screens 29 . We included 79 sgRNAs that target regions of the genome with no annotated function (safe-targeting sgRNAs) as negative controls 29 . A total of 700 sgRNAs ( Supplementary  Table 2 ) directed against 207 drug targets (plus safe-targeting controls) were used to create a CDKO library (DrugTarget-CDKO) comprising 490,000 double-sgRNAs, corresponding to 21,321 drug target combinations ( Fig. 1e) . Cas9-expressing K562 cells were infected with this library and maintained in exponential growth phase for 14 d (~14 cell doublings) in duplicate, after which the frequencies of double-sgRNA cassettes were quantified by deep sequencing.
Precise phenotypic measurements of a large CDKO library
To assess whether the diversity of the large DrugTarget-CDKO library was maintained throughout library generation, delivery, and screening, we examined the distribution of library elements in the plasmid library, post-infection and puromycin selection day 0 (T0), and day 14 (T14) ( Fig. 2a) . 92% of the expected 490,000 double-sgRNAs were detected in both the plasmid and T0 samples, suggesting this large library could be efficiently cloned and delivered to cells. 98.7% of the observed gene pairs had at least six double-sgRNAs, with 75.2% having the maximum of nine double-sgRNA combinations per gene pair ( Fig. 2b) . Since low sequencing read depth could add noise to the data, we filtered out double-sgRNAs that had read counts below the determined minimum threshold ( Supplementary Fig. 2a and Supplementary Table 3 ).
Quantification of GI (deviation of an observed double-knockout phenotype from that expected from the corresponding two single knockouts) requires high-precision phenotypic measurements of both single and double knockouts. We defined growth phenotype quantitatively as gamma (γ) adapted from previous shRNA and CRISPR interference (CRISPRi)-based screens 15, 31, 32 . γ-phenotype is expressed as a phenotype Z score (pZ) 32 by dividing the phenotype by the s.d. of all safe-sgRNA pairs (Safe_Safe). To calculate γ for a single gene, we used the median of all double-sgRNAs in which the three sgRNAs targeting this gene are paired with the 79 safe-sgRNAs ( Fig. 2c) . To calculate the γ of a gene pair, we used the median of the nine double-sgRNAs (3 × 3) targeting the gene pair.
Single-gene γ-phenotypes in the CDKO vector showed strong correlation (Pearson coefficient = 0.87) with γ from previous single-sgRNA genome-wide screens 29 (Supplementary Fig. 2e ), suggesting that the effectiveness of deletion is preserved in our double-sgRNA system. Furthermore, phenotypes of double-sgRNAs ( Fig. 2d ) and corresponding gene pairs ( Supplementary Fig. 2c ) were similar in both orientations, and γ correlated well between experimental replicates ( Fig. 2e and Supplementary Fig. 2d ). Thus, the order of sgRNAs within the double-sgRNA cassettes had minimal impact on knockout efficiency, and measured phenotypes were highly reproducible.
Calculation of GI scores from CRISPR-knockout phenotypes
Previously, we calculated GI of double-shRNAs as the deviation from a linear fit of all double-shRNA phenotypes that combine the same single-shRNA with second shRNAs of interest 15 . To determine whether the same linear relationship could be used to calculate GIs from pairwise CRISPR knockouts, we examined three groups of sgRNAs, with an sgRNA in one position of the double-sgRNA, which causes either a phenotypically weak (sgFABP4_1), medium (sgKDM1A_1), or strong (sgNAMPT_1) sgRNA phenotype (Fig. 3a) . Notably, the NAMPT-containing double-sgRNA phenotypes leveled off as the negative γ-phenotype of the second sgRNAs increased, whereas the FABP4-or KDM1A-containing double-sgRNAs showed linear relationships with second sgRNAs. This suggested that the assumed linear relationship would not always hold true as the phenotype of a double-sgRNA became stronger.
Therefore, to systematically analyze how this relationship changed with the γ-phenotype of double-sgRNAs, we plotted the observed phenotypes against the expected phenotypes for all double-sgRNAs. Expected double phenotypes were calculated as the phenotypic sum of the corresponding single-sgRNAs ( Fig. 3b) . For most sgRNA pairs, we observed a strong linear relationship with slope close to 1, indicating that the observed γ-phenotypes of most double-sgRNAs could be reliably predicted by the simple sums of individual sgRNA phenotypes. However, as the expected γ-phenotypes dropped below ~−20 pZ, the observed γ-phenotypes abruptly leveled off. While limited sequencing depth can contribute to the plateau (Supplementary Fig. 2f ), as discussed below, this can also occur due to phenotypic saturation.
To account for this phenotypic plateau, we calculated GIs between sgRNAs (Raw-GIs) as the deviation from the smoothed line connecting the medians of the observed phenotypes of double-sgRNAs binned over the expected phenotypes, similar to a previous method for quantifying saturable GI phenotypes 8 . We defined GIs as buffering (positive sign) if the double-knockout phenotype shifted toward that of the Safe_Safe controls, while deviations away from Safe_Safe controls were defined as synergistic (negative sign). Buffering GIs have also been referred to as alleviating 7 or positive interactions 6 , whereas synergistic GIs are sometimes referred to as aggravating 7 or negative 6 interactions. 
A r t i c l e s
We also found that the variation of Raw-GIs increased as the negative γ-phenotypes of double-sgRNAs increased (Fig. 3c, top panel) . This systematic bias would thus overestimate the GI for double-sgRNAs with large γ-phenotypes. To account for the increased variation associated with phenotype size, the Raw-GI for a given double-sgRNA was divided by the s.d. of Raw-GIs from the 200 nearest neighbors.
This normalized GI (termed Norm-GI) should allow fair comparison of GIs across the range of γ-phenotypic strengths and experimental replicates (Fig. 3c , bottom panel).
To quantify GIs at the gene level ( Fig. 3 and Supplementary Fig. 3 ), we took advantage of the fact that each pair of genes has 18 different double-sgRNAs (9 for each of two orientations). Furthermore, the library contains many non-interacting double-sgRNA controls: Safe_ Safe (6,241) and sgRNAs paired with a safe-sgRNA (49,059) ( Fig. 3c , bottom panel). This allowed us to compare the double-sgRNAs for each gene pair to these non-interacting sgRNA pairs to calculate scores that reflect both the consistency and strength of GIs. We then tested two scoring systems-GI T score ( Fig. 3d and Supplementary  Fig. 3a ) and GI M score ( Supplementary Fig. 3b )-which are based on a modified t-value 33 A r t i c l e s the Mann-Whitney U test 15 , respectively ( Supplementary Table 4 ). Nearly identical synergistic and buffering gene pairs were identified using each method, suggesting that both scoring systems robustly measure GIs in the DrugTarget-CDKO map. We evaluated gene-level interactions between drug targets in the library as GI T scores ( Fig. 3d) . As expected, genes showed minimal interactions with safe-targeting controls. Furthermore, strong buffering GIs were observed between a gene and itself ( Supplementary Fig. 3c ), suggesting that, overall, the CDKO system achieved efficient doubleknockout since incomplete knockout would lead to more additive or synergistic interactions between two sgRNAs targeting the same genes. A few genes appeared self-synergistic (e.g., TK1_TK1), likely from a disproportionate increase in gene-deletion efficiency when two different ineffective sgRNAs were used to target the same gene ( Supplementary Fig. 4 and Supplementary Text).
As drug targets were chosen from unrelated pathways, most gene pairs did not interact and had small GI T scores, consistent with low interaction frequencies in previous GI maps for unrelated genes 6, 34, 35 (Supplementary Text). Note that the low density and overall small effect of interactions resulted in lower correlations between GIs than the primary gene effects ( Fig. 2d,e ), which are highly reproducible. However, when we looked at the rare synergistic gene pairs that were well separated from the cloud of weakly interacting pairs, a number of strong interactions were observed. These consisted of several pairs with no annotated interaction, as well as many gene pairs for which synergistic interactions are either supported by previous studies or readily explained by the known biological functions of the corresponding genes. For example, the AKT1_AKT2 and PIM1_PIM2 pairs are highly homologous kinase isoforms with known functional redundancy 36, 37 and the BCL2L1_MCL1 and ATM_PRKDC pairs have similar biological functions (apoptosis and DNA damage repair, respectively). Notably, it has been shown that when both PIM1 and PIM2 are deleted, oncogenic ABL-mediated transformation in hematopoietic cells cannot occur 38 . Because K562 growth is driven by BCR-ABL, the results suggest that cancer-specific synthetic lethalities can be identified with the CDKO system. Overall these results suggest that even when interactions are rare, the CDKO system can efficiently identify biologically meaningful synergistic relationships.
Validation of the CDKO system on a dense ricin GI map Although the DrugTarget-CDKO map revealed rare, potent, synergistic targets, another useful feature of GI maps is the ability to cluster functionally related genes by the similarity of their GI patterns 7, 33 .
Since genes for the DrugTarget-CDKO library were selected across a wide variety of pathways, GIs were sparse 6, 7, 34, 35 (Supplementary Text), and consequently did not result in meaningful clustering (with a few exceptions) ( Supplementary Fig. 5 ). Therefore, we sought to rigorously evaluate our CRISPR-based GI map system in a different context, where frequent GIs among functionally related genes yield interaction patterns that can be used to cluster genes into pathways and complexes. For this purpose, we generated a GI map focused on the biology of the AB-type protein toxin ricin, for which we have extensive data on the dense network of known physical, genetic, and functional interactions between regulators of toxicity 15, 39, 40 . We chose a set of 79 non-essential genes that modulated the cellular susceptibility to ricin (Supplementary Tables 5 and 6) in a genomewide CRISPR-Cas9 ricin screen 29 (Supplementary Fig. 6a) , and included both genes identified as ricin regulators in our previous shRNA-based interaction map 15 and novel modifiers identified only in the CRISPR screen. We generated a ricin-CDKO library (80,656 double-sgRNAs for 3,081 gene pairs), and measured the ricin-resistance phenotype (ρ) of double-sgRNAs, as previously described 15 (Supplementary Fig. 6b-f ).
As expected, we observed more frequent and larger GIs between ricin pathway regulators compared to the DrugTarget-CDKO library (Supplementary Fig. 6g ). GIs were highly reproducible between experimental replicates ( Supplementary Fig. 6g and Supplementary  Table 7 ), as were the correlations of GI patterns between sgRNA pairs (Fig. 4a) , though we also observed phenotypic saturation for highly ricin-resistant gene pairs ( Supplementary Fig. 6f, top right) . Furthermore, GI patterns were better correlated between two sgRNAs targeting the same gene, as expected for on-target sgRNAs acting through the same mechanism (Fig. 4a,b) .
We next used hierarchical clustering to generate an interaction map for the 79 × 79 matrix of ricin interactors (Fig. 4c) . The resulting map clearly identified a number of functional complexes with known involvement in ricin biology, including the vesicle-trafficking TRAPP, COPII, and GARP complexes. Our previous shRNA-based interaction map identified two distinct mammalian TRAPP complexes, mTRAPPII and mTRAPPIII, which contain unique subunits (TRAPPC9/10 or TRAPPC12/13, respectively) and associate with either COPI or COPII complexes, respectively 15 . Not only did the ricin-CDKO map separate the TRAPPC9/10 cluster clearly from the TRAPPC12/13 cluster, but these clusters were also grouped with their corresponding COPI or COPII modules.
When we compared 91 common GIs between the ricin-CDKO map and our previous shRNA-based ricin GI map 15 , they showed relatively high correlation (Pearson coefficient = 0.606, Supplementary Fig. 7a ), suggesting that the new CRISPR-based map recapitulated previously reported interactions. We do note some differences between two ricin maps, which is not unexpected given that we and others have observed significant differences between shRNA-based knockdown and CRISPR KO studies 30, 41 . However, both maps identified common protein complexes such as TRAPPII, TRAPPIII, COPII, and GARP ( Supplementary Fig. 7b ). Overall, these data suggest that functional clustering of genes is robust regardless of gene perturbation methods.
The ricin-CDKO map identified a number of known and previously unidentified protein complexes whose roles in ricin biology remain unexplored. For example, a number of genes involved in protein N-glycosylation, the mTOR pathway, or chromatin remodeling/ transcription control complexes were identified as protective factors against ricin toxicity when deleted ( Fig. 4c) . In each case, the corresponding genes were correctly clustered together in complexes according to previous annotations [42] [43] [44] .
Next, we systematically tested the ability of GIs to predict the 246 known protein-protein interactions (PPIs) present in the STRING 45 database among the 79 genes in the ricin map ( Supplementary Table 8 ). Similar approaches have been successful for systematic validation of GI maps in yeast 10, 33 . We sorted the 3,081 gene pairs present in the ricin-CDKO library by the correlation of their GI patterns, their buffering GIs, or their synergistic GIs and quantified the percentage of the known protein interactions captured by the top N pairs ( Fig. 4d and Supplementary Fig. 8a) . The correlation of GI patterns had a high predictive power for known protein interactions ( Fig. 4d,e) ; among the 66 gene pairs with a GI correlation > 0.5, 32% of the pairs had previously validated interactions, significantly higher than the 4.8% of 66 randomly sorted gene pairs ( Supplementary Fig. 8b and Supplementary Table 9 ). Additionally, we observed that buffering GIs had strong predictive power for PPIs. This is consistent with previous work showing that gene pairs with highly correlated GIs and buffering interactions often exist in the same protein complexes or pathways 7,33 .
A r t i c l e s SLC33A1   TCF3  CUL5  ARIH2  HDAC8  B3GNT2  B4GALT3   TSC2  TSC1  NPRL3  NPRL2  DEPDC5  TRAPPC2L  TRAPPC2P1  TRAPPC5  SEC31A  TRAPPC11   VPS53  VPS51  VPS45  RABGEF1  SEC23B  SEC24C  SAR1A  SEC24B  SEC24A  SEC23IP  HSP90AB1   RAB2A  RAB1B  RAB1A  TRAPPC12  TRAPPC13   RAB5C  KHSRP  ARL5A  PTEN  MAN2A1  MAN1B1  MOGS  FUT8  SLC30A5  SLC39A7  IGF2R  CBL  GCNT2  ARL5B  CUL4A  EP300  EZH2  EED  CTBP1  UBE2J1  CARM1  DCAF7  TBL1XR1  NCOR1  RICTOR  IGF1R  IGF2BP1  UBE2M  CAND1  B4GALT1   MTF2  BMI1  MAN1A1   ARF1  ARFGAP2  HMGCR  DAZAP1  POLE3  BAZ1A  CHRAC1  HNRNPD  SLC39A9  SLC39A3  TRAPPC10  TRAPPC9   SLC33A1  TCF3  CUL5  ARIH2  HDAC8  B3GNT2  B4GALT3  TSC2  TSC1  NPRL3  NPRL2  DEPDC5  TRAPPC2L  TRAPPC2P1  TRAPPC5  SEC31A  TRAPPC11  VPS53  VPS51  VPS45  RABGEF1  SEC23B  SEC24C  SAR1A  SEC24B  SEC24A  SEC23IP  HSP90AB1  RAB2A  RAB1B  RAB1A  TRAPPC12  TRAPPC13  RAB5C  KHSRP  ARL5A  PTEN  MAN2A1  MAN1B1  MOGS  FUT8  SLC30A5  SLC39A7  IGF2R  CBL  GCNT2  ARL5B  CUL4A  EP300  EZH2  EED  CTBP1  UBE2J1  CARM1  DCAF7  TBL1XR1  NCOR1  RICTOR  IGF1R  IGF2BP1  UBE2M  CAND1  B4GALT1  MTF2  BMI1  MAN1A1  ARF1  ARFGAP2  HMGCR  DAZAP1  POLE3  BAZ1A  CHRAC1  HNRNPD  SLC39A9  SLC39A3  TRAPPC10 
Together these results show that the ricin-CDKO map could correctly classify complex functional relationships among ricin modulators.
Validation of top interacting drug target gene pairs
We next sought to verify drug target pairs from the initial DrugTarget-CDKO map, in high throughput, using a 'batch retest' mini-map. In previous studies, we 15 and others 46, 47 have seen that measurement of smaller libraries at higher coverage reduces false positives and/or false negatives from larger primary screens. We selected the top synergistic and buffering pairs from the DrugTarget-CDKO map and generated a mini-map (Supplementary Tables 10 and 11 ) consisting of 82,369 (287 × 287) double-sgRNAs targeting 3,081 drug combinations (79 × 79 genes). Compared to the DrugTarget-CDKO map, the batch retest was performed at 3× higher cell coverage and ~3× higher read coverage. Both γ-phenotypes ( Fig. 5a) and measured GIs (Fig. 5b) in the primary DrugTarget-CDKO and batch retest screens correlated well and identified the same highly synergistic pairs, indicating that hits observed in the large interaction map were robust.
To test individual gene pairs, their respective single-sgRNAs ( Supplementary Table 12 ) were cloned into vectors tagged with either GFP or mCherry. To measure their GIs, we simultaneously infected Cas9-expressing K562 cells with lentiviruses containing each sgRNA to generate four populations of cells: cells that contained both sgRNAs (GFP-mCherry double-positive), one sgRNA (GFP or mCherry single-positive), and uninfected cells (Fig. 5c) . Tracking the change in abundance of each population relative to the uninfected control over time allowed us to measure both the single-and double-knockout growth phenotypes of the sgRNAs, which were subsequently used to calculate the GI. For PIM1_PIM2, a top synergistic pair (Fig. 5d,e) , the double-knockout phenotype was significantly larger (P = 2.1 × 10 −4 ) than the sum of the single-knockout phenotypes, resulting in a synergistic GI, whereas the corresponding negative control pairs did not interact.
GIs for the six most synergistic and three most buffering pairs (ordered by rank-sum of GI T and GI M scores) were individually validated ( Fig. 5e-h and Supplementary Fig. 9a ). Testing several pairs with a second pair of sgRNAs yielded similar results ( Supplementary  Fig. 9b) . A subset of the same pairs were also validated as synergistic with the double-sgRNA vector used in the DrugTarget-CDKO library, whereas the sgRNAs shuffled into predicted non-interacting pairs were confirmed to be non-synergistic ( Supplementary Fig. 9c,d) . A summary of the sgRNA validations is presented in Supplementary  Table 13 . Efficient knockout by the sgRNAs was confirmed by analysis of indel frequency using TIDE 48 (Supplementary Fig. 9e ).
Identification of synergistic drug pairs using a GI map
As cancer therapeutic targets, gene pairs that exhibit both strong synergistic GIs and a severe growth phenotype when targeted in combination would be ideal. To identify these pairs, we exploited the ability of the DrugTarget-CDKO map to simultaneously measure two critical features of gene pairs-γ-phenotypes and GIs. The 30 most synergistic gene pairs with severe γ-phenotypes (<-4 pZ) ( Fig. 6a) included pairs for which no annotated synergy had been observed, as well as gene pairs in related pathways, such as apoptosis modulators, epigenetic modulators, and DNA repair genes ( Supplementary Table 14 ). We selected several candidates based on the availability of highly selective inhibitors and tested whether the pairs of corresponding drugs synergistically inhibited the growth of K562 cells as predicted in the GI map. Overall, we tested 11 drug pairs which resulted in 5 truepositive synergistic interactions, 4 true non-interactions, 1 false positive, and 1 false negative ( Supplementary Table 13 ).
We first examined APEX1_ATM because of its mechanistic similarity to the well-known synthetic lethality between BRCA and PARP. Synthetic lethality between base excision repair (BER) and doublestrand break (DSB) repair has been successfully exploited to treat BRCA-deficient ovarian cancer patients with PARP inhibitors 49 , and APEX1 (BER) and ATM (DSB repair) are involved in the same pathways. We observed potent synergistic inhibition of cell viability using a combination of inhibitors against APEX1 and ATM as calculated by the Bliss independence model (Fig. 6b-d) . Furthermore, the drug pair synergistically induced DSB as shown by the presence of γH2AX foci (Supplementary Fig. 10a-c) , and apoptosis (Supplementary Fig.  10d,e ). Drug synergy was also observed between inhibitors of APEX1 and PRKDC and of ATM and PRKDC (Supplementary Fig. 11a,b) . These results are consistent with recent studies demonstrating synthetic lethality between APEX1 shRNA knockdown and inhibitors of DSB repair, including ATM and PRKDC inhibitors 50 and with the observed behavior of PRKDC inhibitors used in ATM-deficient cancers 51 . Additionally, a synergistic interaction was identified between inhibitors of PRKDC and TSPO (Supplementary Fig. 11c ), which encodes a mitochondrial translocator protein that is thought to play a role in cell death regulation 52 . As expected, TXN_XPO1, MCL1_ PRKDC, TSPO_XPO1, and CARM1_XPO1, predicted to have little interaction, did not show substantial synergy with small-molecule inhibitors (Supplementary Fig. 11d-g) . However, NAMPT_XPO1, predicted to be synergistic, did not show drug synergy (false positive) (Supplementary Fig. 11h) , and BCL2L1_XPO1 demonstrated drug synergy despite having little GI (false negative) ( Supplementary  Fig. 11i) . Overall, these data show that the use of targeted inhibitors could generally recapitulate GIs observed in the DrugTarget-CDKO map.
Because of its strong synergy in the DrugTarget-CDKO map, we also examined combination treatment using BCL2L1 (BCL-X L ) (A-1155463) and MCL1 (A-1210477) inhibitors. Although synergy might be expected between BCL2L1 and MCL1, which encode antiapoptotic proteins of the BCL-2 family, cancers differ markedly in their dependence on particular pro-and anti-apoptotic proteins 53 , and a direct test of combined drug inhibition of BCL2L1 and MCL1 has not been tested in BCR-ABL-driven cancers to our knowledge. We observed robust synergy ( Fig. 6e-g) and induction of apoptosis with these drugs (Fig. 6h,i) . In addition, strong synergy could be seen when the BCL2L1 inhibitor was coupled with another MCL1 inhibitor (UMI-77) ( Supplementary Fig. 11j ), indicating the observed synergy is likely due to on-target effects. Furthermore, combined BCL2L1 and MCL1 treatment was synergistic in MV4-11 acute myeloid leukemia cells (Supplementary Fig. 11k) . Because effective cancer therapeutics require a therapeutic window for cancer-selective toxicity, we additionally tested the BCL2L1 and MCL1 combination treatment in two non-cancerous cell lines-immortalized GM12892 lymphoblastoid cell line (LCL) and primary CD34 + hematopoietic stem-progenitor cells (HSPCs) isolated from human cord blood. The treatment was less effective and synergistic in both cell types ( Fig. 6j ), suggesting this combination may be selective for certain cancer cells over normal cell types.
Although tyrosine kinase inhibitors such as imatinib (Gleevec) that target BCR-ABL have been effective in treating CML, around 33% of CML patients treated with imatinib do not achieve complete cytogenetic response, largely due to resistance 54 . Notably, when applied to imatinib-resistant K562 (K562-r) cells, the BCL2L1_MCL1 drug combination was even more synergistic than in parental K562 cells (Fig. 6k) . We found that K562-r had markedly increased levels of BCL2L1 expression, suggesting a greater dependence upon anti-apoptotic machinery (Fig. 6l) . Given that overexpression of BCL2L1 and MCL1 has been associated with increased cancer cell survival and drug resistance 55 and that K562 cells actively regulate anti-apoptotic machinery in response to imatinib (Fig. 6l) 56, 57 , co-treatment with BCL2L1 and MCL1 inhibitors in addition to imatinib may be an effective strategy to prevent resistance in CML.
DISCUSSION
High-throughput interrogation of cancer dependencies have successfully revealed oncogenes 58, 59 , drug-resistance mechanisms 60, 61 , and synthetic lethal interactions 62, 63 , and have led to the development of new therapies that are now being tested in clinical trials 62, 63 . However, these studies have primarily used single-gene targeting libraries, limiting their capacity to interrogate combinations of targets for effective therapies.
To address this, we developed and optimized a scalable pairwise CRISPR-Cas9 gene-deletion platform that allows for easy cloning, minimized recombination, and paired-end sequencing. We also established robust scoring methods for calculating GIs between CRISPRdeleted gene pairs. This system enabled a rapid search through combinations of drug targets at an unprecedented scale-490,000 sgRNA pairs directed against 21,321 drug target combinations. From this large space of potential candidates, we identified a small number of highly synergistic drug combinations in K562 CML cells. In particular, the BCL2L1_MCL1 drug combination demonstrated a strong synergy. Given the importance of apoptosis evasion in cancer 55 , there has been enormous interest in targeting the anti-apoptotic BCL2 family for cancer therapy 64 . BH3 mimetics such as the BCL2L1/BCL2targeting navitoclax and BCL2-specific venetoclax have demonstrated efficacy in patients in a variety of cancers. Additionally, these molecules can sensitize cancers to other drugs; numerous clinical trials are underway to evaluate these in combination with standard-of-care therapies 55 .
The anti-apoptotic BCL-2 family members act in parallel to block apoptosis, and MCL1 upregulation has been reported as a mechanism of resistance to Bcl-2 family inhibitors in certain cancers 55, 64 and cotargeting of anti-apoptotics has been explored in certain contexts 65, 66 . Our CRISPR-based drug target interaction map identified BCL2L1_ MCL1 as an especially potent synergistic pair in BCR-ABL-driven CML (K562). Furthermore, we showed that imatinib-resistant K562 cells have markedly increased sensitivity to combination BCL2L1 and MCL1 drug treatment. Given that previous studies have shown synergy between imatinib and BCL2 family inhibitors 67 , combining imatinib with both BCL2L1 and MCL1 inhibition may represent an effective strategy to combat resistance in CML.
The results of genetic screens can suggest promising candidates for drug development when potent, selective drugs are unavailable. For example, the GI map identified many promising synergistic drug target pairs such as CDC25A_RELA and CIT_STMN1 that currently lack specific drugs, but represent promising synergistic targets based on their known biological roles in NF-kB signaling 68 and microtubule regulation 69 , respectively ( Supplementary Table 14 ). The map also identified a number of drug targets that show weak synergy or additivity that might have therapeutic value in combination (e.g., TXN_XPO1, for which potent drugs in clinical trials exist, Supplementary Fig. 11d) .
Beyond the ability to search for rare synthetic lethal pairs, we show here that systematic, quantitative phenotypic measurements of interactions between CRISPR-deleted genes can be effectively used to define functional relationships and pathways. Focusing on the wellvalidated physical and genetic interactions of the ricin pathway, we created a dense map of interactions between regulators that correctly classified genes-including previously unidentified ricin modifiers from a genome-wide CRISPR screen-into known physical complexes and pathways. Furthermore, the similarity of interaction patterns accurately predicted membership in protein complexes independently reported in the STRING PPI database (Fig. 4d) .
In summary, our work demonstrates a highly robust, efficient method that can be used to search through the expansive space of potential synergistic drug target pairs for use in cancer therapies, and might even facilitate personalized targeted cancer therapies when applied in diverse cancer types or patient-derived samples. More generally, we expect that this system will enable systematic dissection of genetic networks in mammalian cells.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
Minimum count threshold. We determined a minimum threshold for read counts (Supplementary Fig. 2a ) and masked out double-sgRNAs that have read counts below the threshold. To do this, we first measured frequencies of the single-sgRNAs in both the hU6 and mU6 libraries, calculated expected frequencies of the double-sgRNAs, and compared them to observed frequencies in the CDKO library (Supplementary Fig. 2a ). Ratios of the two frequencies showed that under ~50 read counts, the observed frequencies markedly fell below the expected; therefore, we removed double-sgRNAs with less than 50 read counts at T = 0 from further analyses. Zero count in T14 samples were replaced with count = 1.
Measurement of phenotypes and GIs.
To calculate the phenotype of double-sgRNAs, we compared frequencies of double-sgRNAs between the plasmid library and T14 sample to calculate the growth phenotype (γ) and between the ricin-treated T14 and untreated T14 samples to calculate the ricin-resistance phenotype (ρ) as previously described 31 . In short, we measured the frequency of each double-sgRNA between two samples and calculated the log 2 enrichment ratio (log 2 e) between them, which was then normalized to the median log 2 e of the negative control double-sgRNAs, comprising 79 × 79 Safe_Safe sgRNA pairs. Equations used here are as follows:
Growth phenotype (γ)
Where:
Phe ctrl is the median of Log 2 ((N ctrl-14 /N ctrl-p ) X (C P /C 14 )) of Safe_Safe double-sgRNAs. N 14 : the read counts of a double-sgRNA in the T14 sample N ctrl-14 : the read counts of a Safe_Safe double-sgRNA in the T14 sample N p : the read counts of a double-sgRNA in the plasmid library N ctrl-p : the read counts of a Safe_Safe double-sgRNA in the plasmid library C p : the total read counts of the plasmid library C 14 : the total read counts of the T14 sample D: the number of doublings of the infected cells between infection and T14
Ricin-resistance phenotype (ρ) is calculated in the same way except that read counts are compared between the ricin-treated T14 sample and the ricinuntreated T14 sample instead of the T14 sample and the plasmid library in γ-phenotype.
Lastly, we calculated a phenotype Z score (pZ) 32 by dividing the phenotype of each double-sgRNA by the s.d. of Safe_Safe pairs. To calculate log fold enrichment of double-sgRNAs, we compared counts in T14 to counts in the plasmid library instead of those in the T0, since we observed that genes with large negative growth phenotypes dropped out quickly even between infection and T0 (6 d after infection, puromycin selection for lentiviral integration, and expansion) ( Supplementary Fig. 2b) . To calculate the expected phenotype of double-sgRNAs, we first calculated the phenotype of individual sgRNAs: a phenotype of an individual sgRNA was measured as the median phenotype of all double-sgRNAs comprising this sgRNA and one safe-sgRNA. For example, to calculate the phenotype of AKT1 sgRNA_1, we measured phenotypes of all AKT1 sgRNA_1's paired with any of the 79 safe-sgRNAs and calculated the median of the phenotype distribution. The expected double-sgRNA phenotype was then calculated by summing the phenotypes of the two individual sgRNAs. To measure the GI between two sgRNAs, the expected phenotype of double-sgRNAs were plotted against their observed phenotypes (Fig. 3b) . Data were then binned along the expected phenotype so that each bin contained 200 data points. The median of each bin was measured and the line connecting the median values was then smoothed by a three-point moving averaging filter. The smoothed line represents the typical behavior of double-sgRNAs and deviations from this line were measured to calculate the GIs between sgRNA pairs. Deviations that moved the double-sgRNA phenotypes closer to the phenotype of the Safe_Safe controls were given a positive sign and defined as buffering GIs, while those that moved away from the Safe_Safe phenotype were given a negative sign and defined as synergistic GIs. A signed GI (Raw-GI) was then divided by the s.d. of the Raw-GIs of the 200 (arbitrary number) nearest neighbors along the expected phenotype. This normalized GI (Norm-GI) measures GI between sgRNA pairs, and we found that the normalization sta-bilizes variance of GIs, improving reproducibility of GIs between experimental replicates (Supplementary Fig. 12 ) To calculate a quantitative GI score for a given gene pair, we pooled all double-sgRNAs targeting the same gene pair in both orientations from two experimental replicates. This would give us 36 data points at most for any given gene pair (9 combinations × 2 orientations × 2 replicates). We filtered out gene pairs if they have less than 3 data points. Then, GI scores between gene pairs were defined with two scoring methods. GI T score for a given gene pair was calculated based on the modified t-value score using the following equation (a similarly modified t-value score was used to calculate a quantitative GI score, S score, in budding yeast 33 To calculate the GI M score, the probability that the distribution of Norm-GIs of all double-sgRNAs targeting a given gene pair was significantly different from that of non-interacting double-sgRNAs was measured using the Mann-Whitney U test. A similar concept has been used to score phenotypes of genes from ultracomplex pooled shRNA and CRISPRi screens 15, 32 . Log 10 of P values were then given a positive sign if gene pairs were buffering according to the median of Norm-GIs and a negative sign if gene pairs were synergistic. The two GI scores generally identified similar top buffering and synergistic hits ( Fig. 3e and Supplementary Fig. 3b ) and the rank-sum of the two GI scores was used to prioritize synergistic, toxic gene pairs for subsequent validation with corresponding drugs.
Systematic comparison between GI and PPI.
To systematically compare GI and PPI, we examined the previously reported interactions among 79 ricin modulators from STRING 45 . Among all the validated and predicted PPIs for the 79 ricin modulators, we used only the experimentally validated interactions for the comparison (minimum required interaction score was set to 0.15 in STRING). Gene pairs were then sorted by one of the three features of GIs-buffering GI, synergistic GI, or correlation of GI profiles (Pearson correlation coefficient, uncentered). Here, correlation of GI profiles were calculated as previously described 15, 31, 73 . Next, for a given top N pairs of genes, we measured how many of the pairs have the reported interactions in STRING and plotted the measured percent coverage by the STRING interactions on the y axis against the N number on the x axis ( Fig. 4d) . Functional interactomes of the 66 most correlated gene pairs in terms of GI profiles were drawn using Cytoscape software 74 in Supplementary Figure 8b . Edges were drawn between genes whose correlation of GI profiles were greater than 0.5 and the width of the edges were determined by their GI correlation values. If an interaction was already reported in STRING for a given edge, it was colored in red. Comparison of GIs to PPIs in BioGrid 75 also showed similar results (data not shown).
Constructing GI maps. To construct the GI maps, GI profiles of genes were generated based on GI scores. Genes were then hierarchically clustered with Cluster 3.0 software 76 based on the uncentered Pearson correlation coefficients of their GI profiles as a similarity metric and average linkage as the clustering method. Generated clusters were displayed using Java TreeView 77 . Both GI M score and GI T score identified similar clusters.
Validation of identified GIs using individual sgRNAs.
For each gene pair, we selected the pair of sgRNAs that showed the greatest GI in the DrugTarget-CDKO screen. The first sgRNA in the pair was cloned into a sgRNA expression vector (pMCB306), which expresses GFP-T2A-puromycin from an EF-1 alpha promoter. The second sgRNA was cloned into a vector (pMCB320) that expresses mCherry-T2A-puromycin. Two lentiviruses were produced separately and pooled together to infect Cas9-expressing K562 cells. We adjusted virus titers so that the infection generated four populations of cells: uninfected, GFP-positive, mCherry-positive, and GFP-mCherry double positive. The single knockout phenotype for each sgRNA was measured by comparing the abundance of either GFP-positive or mCherry-positive cells relative to the uninfected cells between T0 (day 5 post-infection) and T7 (day 12 post-infection). Similarly, the double-knockout phenotype was measured by comparing the relative abundance of the double positive cells between T0 and T7. Log 2 enrichment of each population divided by 7 (the estimated number of doublings) was used to calculate the growth phenotype. GI was calculated as the difference between the expected phenotype (sum of two single-knockout phenotypes) and the observed phenotype of the double knockout. The GI between two gene-targeting sgRNAs was compared to GIs from each individual sgRNA paired with a safe-sgRNA as non-interacting controls. The statistical significance (P value) used to compare the average phenotype or GI of two samples was determined by unpaired, two-tailed Student's t-test implemented in Microsoft Excel.
Sequencing analysis for indel detection. Genomic DNA was extracted from cells using a QIAamp DNA mini kit (Qiagen). A ~600-to 700-bp region containing the sgRNA cut site was amplified by PCR. The PCR product was run on a 0.8% TAE-agarose gel, bands containing the amplicons were excised, and DNA was purified from the gel slice using a QIAquick Gel Extraction kit (Qiagen). Samples were sent for Sanger sequencing. To assess indel frequency, TIDE was used to compare the sequence trace files from the test sample containing the targeting sgRNA to a control sample containing a safe-targeting sgRNA and quantify the distribution of indels in the test sample 48 .
Cell viability assay for drug synergy. Cells were seeded in 24-well plates and treated with no drug, single drug, or in combination at the indicated concentrations for 72 h. For the drug synergy tests, drug pairs were tested in wild-type K562 cells without Cas9, and thus represent effects independent of possible Cas9-induced DNA damage. The final concentration of DMSO in each well was <0.4%, an amount determined to have no observable toxicity in K562 cells. Following drugs were used for the assay: A-1155463 (Chemietek CT-A115), A-1210477 (Chemietek CT-A121), CRT0044876 (Selleckchem S7449), KU-60019 (Selleckchem S1570), UMI-77 (Sigma SML1492), NU 7441 (Selleckchem S2638), PK-11195 (Enzo BML-CM118), PX-12 (Cayman 14192), KPT-330 (Selleckchem S7252), 1-benzyl-3,5-bis-(3bromo-4-hydroxybenzylidene)piperidin-4-one (Millipore 217531), FK866 (Selleckchem S2799). K562 cells were seeded at 100,000 cells/ml, MV4-11 cells were seeded at 200,000 cells/ml, and GM12892 cells and CD34+ HSPCs were seeded at 300,000 cells/ml. After 72 h incubation, the number of viable cells was counted by flow cytometry (FSC/SSC) using a BD Accuri C6 flow cytometer. Drug synergy was evaluated using the Bliss independence model (Bliss CI, 1939). Briefly, the predicted fractional growth inhibition of the drug combination is calculated using the equation F A + F B -(F A x F B ), where F A and F B are the fractional growth inhibitions of the individual drugs A and B at a given dose. Bliss excess is the difference between the expected growth inhibition and the observed inhibition from the drug combination. Bliss scores greater than zero, close to zero, and less than zero denote synergy, additivity, and antagonism, respectively. Bliss sum is the sum of individual Bliss scores in the 3 × 3 matrix of drug doses. P values where indicated were determined by one-tailed Student's t-test between the observed effect of the drug combination and the expected effect calculated from the individual drug effects.
Apoptosis assay. K562 cells were seeded in 24-well plates at 100,000 cells/ml and treated with no drug, single drug, or in combination at the indicated concentrations for 48 h. After 48 h treatment, apoptosis was measured using an Annexin V-FITC Apoptosis Kit (BioVision). Cells were collected and incubated with Annexin V-FITC and propidium iodide (PI) before quantification using a BD Accuri C6 flow cytometer.
Immunoblot analysis. Whole-cell protein extracts were prepared using lysis buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, and 1% Triton X-100 supplemented with Protease Inhibitor Cocktail (Sigma-Aldrich). Samples (100 µg of protein) were separated by SDS-PAGE and transferred to PVDF membranes. Immunoblot analysis was performed using Rabbit anti-Bcl-xL (CST 2762S), Rabbit anti-Mcl-1 (CST 4572S), Mouse anti-tubulin (Sigma T6199), Goat anti-rabbit IRDye 800CW (LI-COR 926-32211), and Donkey anti-mouse IRDye 680LT (LI-COR 926-68022) antibodies, and imaged on a Li-Cor Odyssey Infrared Imaging System. gH2AX flow cytometric analysis and immunofluorescence microscopy. K562 cells were seeded in six-well plates at 250,000 cells/ml and treated with no drug, single drug, or in combination at the indicated concentrations for 48 h. Cells were washed in PBS, fixed in 4% paraformaldehyde for 10 min, washed twice in PBS, permeabilized/blocked in 0.1% Triton/2% BSA/PBS for 30 min, washed twice in PBS, probed with anti-γH2AX monoclonal antibody (Millipore 05-636) for 1 h, washed twice in PBS, incubated with Alexa Fluor 488 goat anti-mouse IgG secondary antibody (Invitrogen A-11029) for 45 min, and washed twice in PBS before quantification using a BD Accuri C6 flow cytometer. Remaining cells were stained with Hoescht 33342 (ThermoFisher Scientific) for 10 min, washed twice with PBS, and mounted on coverslips in ProLong Gold (Thermo Fisher). Cells were imaged with a Nikon Ti-E spinning disk microscope at 100× magnification. Data availability. Sequencing data are available at Sequence Read Archive accession number SRP099805 under BioProject accession number PRJNA374750. Plasmids and their sequences are deposited at Addgene. Scripts used for analysis of sequencing data are available upon request.
